Results 51 to 60 of about 72,405 (280)

Infliximab-Induced Pneumonitis in a Patient With Sarcoidosis: A Case Report

open access: yesOpen Respiratory Archives
Infliximab, a tumor necrosis factor alpha (TNF-α) inhibitor, is recommended in selected cases of pulmonary sarcoidosis. Although infectious complications are well recognized, non-infectious pulmonary toxicity is less frequently reported.
Alexander Ali Jiménez Romero   +3 more
doaj   +1 more source

Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review

open access: yesAmerican Journal of Ophthalmology Case Reports, 2022
Purpose: To investigate the clinical response to infliximab in ocular inflammation patients who develop anti-infliximab antibodies (AIA) vs. those patients who do not develop AIA.
Lianna Valdes   +6 more
doaj   +1 more source

Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data.

open access: yesArthritis &Rheumatology, Accepted Article.
Background Little is known about the prevalence of and factors associated with Long COVID in patients with autoimmune rheumatic diseases (AIRDs). Methods We conducted a retrospective cohort study using data from the National Clinical Cohort Collaborative (N3C).
Namrata Singh   +11 more
wiley   +1 more source

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen   +4 more
wiley   +1 more source

Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit

open access: yes, 2022
International audienceSubcutaneous infliximab recently received approval for the treatment of various immune-mediated inflammatory diseases in Europe, following pivotal clinical trials in patients with rheumatoid arthritis and inflammatory bowel disease.
Alten, Rieke   +4 more
core   +1 more source

British National Formulary Guidance on prescribing in pregnancy: A descriptive cross‐sectional study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To assess how well pregnancy‐specific guidance within the British National Formulary supports healthcare professionals to facilitate safe and effective medication use. Methods We performed a manifest content analysis of the text of all pregnancy sections within British National Formulary drug monographs, with inductive and iterative coding.
Hannah Johnson   +9 more
wiley   +1 more source

Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial

open access: yesScientific Reports, 2018
We compared the efficacy and safety of infliximab with intravenous immunoglobulin (IVIG), a standard therapy, in a phase 3 trial (NCT01596335) for Japanese patients with Kawasaki disease (KD) showing persistent fever after initial IVIG.
Masaaki Mori   +15 more
doaj   +1 more source

Monitoring patients treated with anti-TNF- biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

open access: yes, 2007
Objectives. Infliximab is an anti-tumour necrosis factor-alpha (TNF-alpha) mousehuman IgG1/k antibody used to treat patients with rheumatoid arthritis (RA) and other inflammatory diseases.
Svenson, M.   +9 more
core   +1 more source

Prevalence of pregnancy and birth outcomes following biologic exposure in immune‐mediated inflammatory diseases: A population‐based study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Almost 5% of pregnancies are affected by immune‐mediated inflammatory diseases (IMIDs). As treatments become available, understanding their use during pregnancy is important. We aimed to describe maternal, pregnancy and infant outcomes among IMID pregnancies exposed to biologic therapies. Methods Using the Merative™ MarketScan® Commercial Database,
Leah K. Flatman   +3 more
wiley   +1 more source

Erythema dyschromicum perstans (ashy dermatosis) during the treatment with infliximab in a child with Crohn disease

open access: yes, 2014
Introduction . Erythema dyschromicum perstans (EDP) or ashy dermatosis is a rare, benign acquired disease characterized by macular hyperpigmentations.
Michał Sobjanek   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy